BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER2-positive Metastatic Breast Cancer|Metastatic Gastroesophageal Junction Adenocarcinoma|Metastatic Gastric Adenocarcinoma
Interventions: DRUG: BI-1607|DRUG: BI-1607|DRUG: Trastuzumab
Sponsor: BioInvent International AB